Antivascular Ultrasound Therapy Extends Survival of Mice With Implanted Melanomas
- 1 May 2010
- journal article
- research article
- Published by Elsevier in Ultrasound in Medicine & Biology
- Vol. 36 (5) , 853-857
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Delta-projection Imaging on Contrast-enhanced Ultrasound to Quantify Tumor Microvasculature and PerfusionAcademic Radiology, 2009
- High-Intensity Focused Ultrasound in Small Renal MassesAdvances in Urology, 2008
- The Disruption of Murine Tumor Neovasculature by Low-intensity Ultrasound—Comparison Between 1- and 3-MHz Sonication FrequenciesAcademic Radiology, 2008
- The Antivascular Action of Physiotherapy Ultrasound on A Murine Tumor: Role of A Microbubble Contrast AgentUltrasound in Medicine & Biology, 2007
- Characterizing the Tumor Response to Treatment With Combretastatin A4 PhosphateInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Vascular disrupting agents in clinical developmentBritish Journal of Cancer, 2007
- The Pharmacokinetics and Safety of ABT-751, a Novel, Orally Bioavailable Sulfonamide Antimitotic Agent: Results of a Phase 1 StudyClinical Cancer Research, 2006
- Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic ResultsJournal of Clinical Oncology, 2003
- Histopathological changes associated with high intensity focused ultrasound (HIFU) treatment for localised adenocarcinoma of the prostateJournal of Clinical Pathology, 2000
- Vascular occlusion and tumour cell deathEuropean Journal of Cancer and Clinical Oncology, 1983